API | spebrutinib

spebrutinib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Chemistry

SMILES: COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1
InChIKey: KXBDTLQSDKGAEB-UHFFFAOYSA-N
Mol. Mass: 423.45
ALogP: 4.25 Partition coefficient
ChEMBL Molecules:

spebrutinib

spebrutinib besylate

More Chemistry

Pharmacology

Mechanism of Action:
- Tyrosine-protein kinase BTK (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

avl-292 | cc-292 | n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide | spebrutinib | spebrutinib besylate

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Arthritis, Rheumatoid (Phase 2)

Healthy Volunteers (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue